Lyell Immunopharma, Inc. (LYEL)

2,7700 +0,0600 (+2,21%) Al cierre: 04:00PM EDT

Lyell Immunopharma, Inc.

201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://lyell.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 224

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Richard D. Klausner M.D.	Founder & Executive Chairman	80k	N/A	1952
Dr. Lynn Seely M.D., Ph.D.	President, CEO & Director	962,23k	N/A	1959
Mr. Charles W. Newton	Chief Financial Officer	744,74k	N/A	1971
Mr. Stephen J. Hill	Chief Operating Officer	775,97k	N/A	1970
Dr. Gary Lee Ph.D.	Chief Scientific Officer	889,68k	N/A	1977
Mr. Matthew Lang J.D.	Chief Business Officer, Chief Legal Officer & Corporate Secretary	596,25k	N/A	1976
Prof. Stanley R. Riddell M.D.	Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Crystal L. Mackall M.D.	Founder & Scientific Advisor	N/A	N/A	1961
Nellie Dillery	Director of Accounting	N/A	N/A	N/A
Ms. Ellen Rose	Senior Vice President of Communications & Investor Relations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Lyell Immunopharma, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.